St. Jude Medical's Unify and Fortify
This article was originally published in The Gray Sheet
Executive Summary
Firm's Unify cardiac resynchronization therapy defibrillator and Fortify implantable cardioverter defibrillator gain FDA approval, announced May 12. The devices feature 45 Joules of stored energy and can deliver 40 Joules - "the highest energy of any ICD available today," the company claims. The implants also have "the smallest device footprint in the industry and rapid charge times, without any compromise in device longevity," the firm states. Their debut positions St. Jude to gain market share "over the balance of 2010 and well into 2011," states J.P. Morgan analyst Michael Weinstein. Separately, St. Jude announced the European launch of its Promote Quadra CRT-D on May 11. The latter device incorporates the first quadripolar pacing system available, and the four pacing electrodes on the left ventricular lead enable up to 10 pacing configurations, according to the company
You may also be interested in...
New Products In Brief
Health Net Connect’s VideoDoc
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.